Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02863003

Multicenter Database of Patients With Germ Cell Tumor

Neoplasms, Germ Cell and Embryonal Clinical Trial

Official title:
Multicenter Database of Patients With Germ Cell Tumor in Order to Characterize Clinicopathologically and to Evaluate Cancer Treatment Outcomes

Clinical Trial Summary

Retrospective and prospective cohort of patients with germ cell tumor in treatment.

Clinical Trial Description

The primary objective of this study is to create a multicenter database in order to characterize epidemiologically and clinicopathologically patients with germ cell tumor and evaluate the prognosis and clinical outcomes during cancer treatment. ;

Study Design

Related Conditions & MeSH terms

  • Neoplasms, Germ Cell and Embryonal
Clinical Trial Details
NCT number NCT02863003
Study type Observational [Patient Registry]
Source Latin American Cooperative Oncology Group
Contact
Status Completed
Phase
Start date September 2016
Completion date December 2020
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Active, not recruiting NCT02533765 - Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor Phase 2
Active, not recruiting NCT00393861 - Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients Phase 2
Completed NCT02679950 - Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse
Completed NCT03403777 - Avelumab in Refractory Testicular Germ Cell Cancer. Phase 2
Recruiting NCT04949282 - Spanish Series of Patients Treated With the Radionuclide Lutetium177
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Completed NCT04657315 - Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients Phase 1/Phase 2
Withdrawn NCT02839694 - Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy Phase 1
Completed NCT03012620 - Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types Phase 2
Active, not recruiting NCT04222972 - A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Phase 3
Completed NCT00611962 - Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin Phase 2
Enrolling by invitation NCT04697446 - External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
Terminated NCT02859415 - Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Phase 1/Phase 2
Available NCT05592743 - Vorasidenib Expanded Access Program